HORRAD试验:原发骨转移前列腺癌ADT联合前列腺放疗的患者报告生活质量
HORRAD多中心随机对照试验纳入432例原发骨转移前列腺癌患者,随机接受ADT联合前列腺EBRT或单用ADT。联合治疗组在治疗初期报告更多腹泻、肠道和泌尿症状,泌尿症状6个月时消退,但2年时肠道症状评分仍显著较高,22%患者肠道功能恶化持续存在,而总体健康相关生活质量未下降。
要点
- ADT联合前列腺EBRT较单用ADT增加暂时性泌尿和肠道症状。
- 泌尿症状在6个月时消退,2年时仅肠道症状评分显著差异。
- 22%患者2年时肠道功能恶化持续,但总体HRQoL未下降。
核心结论
- 骨转移前列腺癌患者接受前列腺EBRT联合ADT后报告暂时性轻度泌尿和肠道症状,部分患者2年时肠道功能恶化持续存在,但总体HRQoL未下降。
研究设计与样本
- HORRAD试验为多中心随机对照试验,2004至2014年招募432例原发骨转移前列腺癌患者,随机分入ADT联合EBRT组或单用ADT组。
主要发现
- 联合治疗组较单用ADT组报告显著更多腹泻(组间差异10.8,95%CI 7.3-14.2)、肠道症状(4.5,95%CI 2.1-6.8)和泌尿症状(11.9,95%CI 8.9-14.8),均p<0.001。
- 泌尿症状在6个月时消退;2年时仅肠道症状评分显著差异(8.0,95%CI 4.8-11.1,p≤0.001)。
- 放疗组68%患者未报告肠道症状评分有临床相关恶化,22%患者2年时肠道功能恶化持续存在。
临床怎么用
- 临床决策时需告知患者联合前列腺放疗可能带来暂时性泌尿和肠道症状,部分患者肠道症状可能持续至2年。
- 总体HRQoL未因联合治疗而下降,支持在适合患者中考虑ADT联合前列腺EBRT。
局限性
- 问卷完成率从基线98%降至24个月58%,高失访率可能影响结果解释。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A survival benefit was demonstrated for patients with low-volume metastatic prostate cancer (mPCa) when local radiotherapy was added to androgen deprivation therapy (ADT). OBJECTIVE: To determine the effect of ADT combined with external beam radiotherapy (EBRT) to the prostate on health-related quality of life (HRQoL) of patients with primary bone mPCa. DESIGN, SETTING, AND PARTICIPANTS: The HORRAD trial is a multicentre randomised controlled trial recruiting 432patients with primary bone mPCa between 2004 and 2014. INTERVENTION: Patients were randomised to ADT with EBRT or to ADT alone. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Patients completed two validated HRQoL questionnaires (European Organization for Research and Treatment of Cancer [EORTC] Quality of Life Questionnaire Core Module (QLQ-C30) and EORTC Quality of Life Questionnaire Prostate Module [QLQ-PR25]) at baseline and at 3, 6, 12, and24 mo after the initiation of treatment. The effect of both treatments was evaluated based on mixed-effect models. RESULTS AND LIMITATIONS: Patient characteristics and HRQoL scores at baseline were similar in both arms. At baseline, 98% of patients completed the questionnaires, compared with 58% at 24 mo. Patients reported significantly more diarrhoea (difference between the groups 10.8; 95% confidence interval [CI] 7.3-14.2), bowel symptoms (4.5; 95% CI 2.1-6.8), and urinary symptoms (11.9; 95% CI 8.9-14.8) after EBRT and ADT compared with ADT alone (all between-arm difference p < 0.001). Urinary complaints levelled at 6 mo. At 2 yr, only bowel symptom scores were significantly different (8.0; 95% CI 4.8-11.1, p ≤ 0.001), but 68% of patients in the radiotherapy group did not report clinically relevant worsening of their bowel symptom scores. CONCLUSIONS: Patients with bone mPCa reported temporary modest urinary and bowel symptoms after combined treatment with EBRT of the prostate and ADT compared with ADT alone. For some patients (22%), deterioration of bowel functions remains at 2 yr, whereas general HRQoL does not deteriorate.. PATIENT SUMMARY: This study investigated the effect of radiotherapy to the prostate added to hormonal therapy on patient-reported health-related quality of life (HRQoL) in patients with primary bone metastatic prostate cancer. Most patients reported only temporary urinary and bowel symptoms. In 22% of patients, bowel symptoms remained at 2 yr, whereas general HRQoL did not deteriorate.
引用
- Boevé L, Hulshof MCCM, Verhagen PCMS, et al. Patient-reported Quality of Life in Patients with Primary Metastatic Prostate Cancer Treated with Androgen Deprivation Therapy with and Without Concurrent Radiation Therapy to the Prostate in a Prospective Randomised Clinical Trial; Data from the HORRAD Trial. Eur Urol. 2020. PMID: 32978014. doi:10.1016/j.eururo.2020.08.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。